已收盘 02-06 16:00:00 美东时间
+5.890
+2.87%
Kayne Anderson Energy Infrastructure Fund, Inc. reported net assets of $2.5 billion as of January 31, 2026, with a net asset value per share of $14.55. The company’s asset coverage ratios under the 1940 Act were 658% for senior securities and 495% for total leverage. The portfolio consisted of 95% Midstream Energy Companies, 4% Power Infrastructure Companies, and 1% Other investments, with the top ten holdings comprising 62.3% of long-term invest...
02-02 23:50
Targa Resources (TRGP) declared $1.00/share quarterly dividend, in line with previous. Forward yield 2.2% Payable Feb. 13; for shareholders of record Jan. 30; ex-div Jan. 30. For the first quarter of ...
01-16 21:02
<p>Targa Resources Corp. announced a quarterly dividend of $1.00 per common share for the fourth quarter of 2025, payable February 13, 2026. The company plans to recommend a dividend increase of $1.25 per share for the first quarter of 2026, subject to board approval. Targa will report its fourth-quarter 2025 financial results on February 19, 2026, and host a webcast at 10:00 a.m. Central Time to discuss the results.</p>
01-15 22:00
Lower-quality stocks have historically outperformed quality in a "dash to trash" in January, according to BofA. Quality stocks have factors such as consistent earnings growth, strong cash flow, high p...
01-07 21:51
Targa Resources Corp. announced the completion of its $1.25 billion cash acquisition of Stakeholder Midstream, LLC, effective January 1, 2026. Targa, a Fortune 500 and S&P 500 company, is a leading North American midstream infrastructure provider, connecting natural gas and NGLs to growing markets for cleaner fuels and feedstocks.
01-06 21:00
Targa Resources (NYSE:TRGP) has outperformed the market over the past 10 years ...
01-06 00:15
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
2025-12-19 10:15
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54
今日重点评级关注:Guggenheim:维持Cybin Inc. Common Shares"买入"评级,目标价从39美元升至48美元;HC Wainwright & Co.:维持Capricor Therapeutics"买入"评级,目标价从24美元升至60美元
2025-12-04 09:38